Adherence and persistence of daily and twice-weekly teriparatide treatment in postmenopausal women with high-risk of fracture.

Mochizuki T, Yano K, Ikari K, Okazaki K

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry24 Oct 2025

PMID41253008DOI10.1016/j.jocd.2025.101641PepBankPUB-41253008

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther
In postmenopausal women at high fracture risk, persistence was 66.7% with daily versus 59.6% with twice-weekly teriparatide, without significant difference.
In plain wordsIn postmenopausal women at high fracture risk, persistence did not differ significantly between daily and twice-weekly teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePersistence by dosing frequency
Study
n = 98
Comparator
Twice-weekly teriparatide
Outcome group
Treatment adherence and retention · Musculoskeletal
Measurements
Persistence rate
66.7%
daily teriparatide (D-TPTD), 24 months
Persistence rate
59.6%
twice-weekly teriparatide (TW-TPTD), 24 months
Source sentences
Summary
The persistence rates at 24 months in the d-TPTD and TW-TPTD groups were 66.7 % and 59.6 %, respectively, with no significant difference between the two.
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-eight postmenopausal women diagnosed with a high risk for fractures were enrolled and randomized into two groups to receive daily (D-TPTD) or twice-weekly (TW-TPTD) teriparatide.
Summary · context
MPR was calculated as the number of days the patient was actually covered by the administered medication divided by the number of days of the study period, which was theoretically 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4125300801
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among teriparatide-treated postmenopausal women, adherence was lower without baseline vertebral fracture than with baseline vertebral fracture.
In plain wordsAmong teriparatide-treated postmenopausal women, adherence was lower without a baseline vertebral fracture than with one.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAdherence by baseline vertebral fracture
Study
n: not reported in source
Comparator
Patients with baseline vertebral fracture
Outcome group
Treatment adherence and retention · Musculoskeletal
Source sentences
Summary
Additionally, adherence and persistence in patients without vertebral fracture at baseline were lower than those with vertebral fracture.
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-eight postmenopausal women diagnosed with a high risk for fractures were enrolled and randomized into two groups to receive daily (D-TPTD) or twice-weekly (TW-TPTD) teriparatide.
Summary · context
MPR was calculated as the number of days the patient was actually covered by the administered medication divided by the number of days of the study period, which was theoretically 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4125300802
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
Among teriparatide-treated postmenopausal women, absence of baseline vertebral fracture was linked to lower persistence, with hazard ratio 0.369.
In plain wordsAmong teriparatide-treated postmenopausal women, persistence was lower without a baseline vertebral fracture than with one.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePersistence by baseline vertebral fracture
Study
n: not reported in source
Comparator
Patients with baseline vertebral fracture
Outcome group
Treatment adherence and retention · Musculoskeletal
Measurements
Persistence hazard ratio
0.369 ratio
without versus with vertebral fracture
Source sentences
Summary
In the Cox proportional hazards analysis, treatment persistence in patients without vertebral fracture was lower than that in patients with vertebral fracture (p = 0.027; hazard ratio, 0.369; 95 % confidence intervals, 0.15-0.89).
2 context sentences(design, population, supporting numbers)
Summary · context
Ninety-eight postmenopausal women diagnosed with a high risk for fractures were enrolled and randomized into two groups to receive daily (D-TPTD) or twice-weekly (TW-TPTD) teriparatide.
Summary · context
MPR was calculated as the number of days the patient was actually covered by the administered medication divided by the number of days of the study period, which was theoretically 24 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-4125300803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.